The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline
Overview
Authors
Affiliations
A new model of Parkinson's disease (PD) pathogenesis is proposed, the α-Synuclein Origin site and Connectome (SOC) model, incorporating two aspects of α-synuclein pathobiology that impact the disease course for each patient: the anatomical location of the initial α-synuclein inclusion, and α-synuclein propagation dependent on the ipsilateral connections that dominate connectivity of the human brain. In some patients, initial α-synuclein pathology occurs within the CNS, leading to a brain-first subtype of PD. In others, pathology begins in the peripheral autonomic nervous system, leading to a body-first subtype. In brain-first cases, it is proposed that the first pathology appears unilaterally, often in the amygdala. If α-synuclein propagation depends on connection strength, a unilateral focus of pathology will disseminate more to the ipsilateral hemisphere. Thus, α-synuclein spreads mainly to ipsilateral structures including the substantia nigra. The asymmetric distribution of pathology leads to asymmetric dopaminergic degeneration and motor asymmetry. In body-first cases, the α-synuclein pathology ascends via the vagus to both the left and right dorsal motor nuclei of the vagus owing to the overlapping parasympathetic innervation of the gut. Consequently, the initial α-synuclein pathology inside the CNS is more symmetric, which promotes more symmetric propagation in the brainstem, leading to more symmetric dopaminergic degeneration and less motor asymmetry. At diagnosis, body-first patients already have a larger, more symmetric burden of α-synuclein pathology, which in turn promotes faster disease progression and accelerated cognitive decline. The SOC model is supported by a considerable body of existing evidence and may have improved explanatory power.
Andersen K, Krishnamurthy A, Just M, Van Den Berge N, Skjaerbaek C, Horsager J Nat Neurosci. 2025; .
PMID: 40082617 DOI: 10.1038/s41593-025-01910-9.
Wang E, Jia Y, Cheng L, Mao C, Bao Y, Shen J Front Aging Neurosci. 2025; 17:1512130.
PMID: 40018517 PMC: 11865091. DOI: 10.3389/fnagi.2025.1512130.
Cholinergic degeneration and early cognitive signs in prodromal Lewy body dementia.
Woo K, Kim H, Kim R, Jin B, Shin J, Kim S Alzheimers Dement. 2025; 21(2):e14584.
PMID: 39985502 PMC: 11846479. DOI: 10.1002/alz.14584.
Theologidis V, Ferreira S, Jensen N, Gomes Moreira D, Ahlgreen O, Hansen M Acta Neuropathol Commun. 2025; 13(1):32.
PMID: 39962601 PMC: 11834571. DOI: 10.1186/s40478-025-01948-7.
Pasquini J, Firbank M, Best L, Foster V, Stewart C, Silani V Brain Commun. 2025; 7(1):fcaf023.
PMID: 39926608 PMC: 11806417. DOI: 10.1093/braincomms/fcaf023.